Who is sponsoring NCT01105624?

NCT01105624 is sponsored by Merck Sharp & Dohme LLC.

What drugs are being tested in NCT01105624?

Interventions in NCT01105624: azithromycin ophthalmic solution, 1%, Visine® for Contacts®.

What condition does NCT01105624 study?

NCT01105624 studies Contact Lens Dry Eye.

Is NCT01105624 still recruiting?

NCT01105624 is currently completed. Last updated 20 September 2011.

Last reviewed 2011-09-20 · How we verify

NCT01105624

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)

Completed Phase 4 Last updated 20 September 2011

What this trial tests

Phase 4 trial testing azithromycin ophthalmic solution, 1% in Contact Lens Dry Eye in 50 participants. Completed in 1 November 2010.

Timeline

1 March 2010

Primary endpoint
1 November 2010

1 November 2010

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 March 2010
Primary completion	1 November 2010
Estimated completion	1 November 2010
Sites	1 location across United States

Drugs / interventions tested

azithromycin ophthalmic solution, 1% — full drug profile →
Visine® for Contacts® — full drug profile →

Conditions studied

Contact Lens Dry Eye — all drugs for Contact Lens Dry Eye →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

18 and older, any sex, with Contact Lens Dry Eye. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Subject-reported comfortable contact lens daily wear time (hours/day) at Week 4 Endpoint
Time frame: 4 weeks

Sponsor's own description

The primary objective of this study is to compare the duration of subject reported comfortable contact lens daily wear time in subjects with a history and current complaint of CLDE during a 29-day treatment period of azithromycin ophthalmic solution, 1%, compared to rewetting drops

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye.
Nichols JJ, Bickle KM, Zink RC, Schiewe MD, et al · · 2012 · cited 24× · PMID 22157392 · DOI 10.1097/icl.0b013e31823ff229
Delivering macrolide antibiotics to heal a broken heart - And other inflammatory conditions.
Venditto VJ, Feola DJ. · · 2022 · cited 10× · PMID 35367307 · DOI 10.1016/j.addr.2022.114252
Lubricating drops for contact lens discomfort in adults.
Caffery B, Pucker AD, Chidi-Egboka NC, Obinwanne CJ, et al · · 2024 · cited 3× · PMID 39234924 · DOI 10.1002/14651858.cd015751.pub2

Verify or expand the search:

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01105624 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 20 September 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01105624.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing